TORONTO (SHfn) – Assays from a project in Sumatra propelled a junior explorer, while a biomedical firm’s virus test received FDA clearance.
Shares of East Asia Minerals (TSX: V.EAS, Stock Forum) soared 30% to $1.56 Wednesday, after the company reported assays for the first two diamond drill holes at its flagship Miwah Gold Project in Sumatra. Highlights include drill hole EMD001, which encountered 1.97 g/t gold over 57.1 metres, including 2.78 g/t gold over 38.3 metres, while EMD002 encountered 1.71 g/t gold over 158.0 metres, including 3.29 g/t gold over 66.0 metres.
Corex Gold Corp. (TSX: V.CGE, Stock Forum) reported additional drill results as well as new mineralized intercepts that were calculated using a 0.3 g/t cut-off from its Santana property in Mexico. The company says that following previous results released in January, it decided to send an additional 336 samples surrounding the mineralized intersections for assaying, which confirm that the width of the mineralized zones has been under-reported in the previous release. Highlights of the results include hole SR08-05, with 91.5 meters @ 1.05 g/t Au, and SR08-06, with 59.5 meters @ 1.23 g/t Au. Shares of the company climbed 17.6% to 40 cents.
Carbon Friendly Solutions (TSX: V.CFQ, Stock Forum) shares jumped 24% to 41 cents as the Vancouver-based company reported after Tuesday’s market close that it has appointed former Minister of Environment for British Columbia and former official opposition house leader, the Honourable John D. Reynolds, P.C., to its board of directors. The company is involved in the development of carbon sequestration projects through the planting of forests in order to generate carbon emission credits which can be traded through institutions and purchasers.
Vancouver-based Response Biomedical Corporation (TSX: T.RBM, Stock Forum) announced that it received a U.S. FDA 510(k) clearance to market a rapid Respiratory Syncytial Virus test. The test, used to detect the presence of RSV F-protein antigens, is manufactured by Response Biomedical and will be marketed and sold by 3M Health Care as the 3M Rapid Detection RSV Test, says the company. Shares of Response Biomedical were up 10.7% to 15.5 cents.
| Top Canadian Small/Micro-cap Advancers (as of 4 PM Eastern) |
| Top Canadian Small/Micro-cap Decliners |